| Olaparib |
HCC-1428 BRCA1 mutant breast cancer cell line |
cytotoxic |
[32] |
| MDA-MB-231, MDA-MB-157 and HCC1143 TNBC cell lines |
cytotoxic |
[31] |
| MDA-MB-468TNBC cell line |
cytoprotective |
[33] |
| SUM159 and MDA-MB-468; as well as their Olaparib-resistant counterparts, SUM159-R and MDA-MB-468-R TNBC cell lines |
Nonprotective |
[34] |
|
BRCA1 null UWB, and BRCA1 restored UWB ovarian cancer cell lines |
Non-protective with BRCA1 restored UWB |
[37] |
| A2780 (BRCA wild type) ovarian cancer cell line |
cytotoxic |
[38] |
| OVCAR8, HEY, A2780 and SKOV3 ovarian cancer cell lines |
cytoprotective |
[29] |
| A2780 and SKOV3 (BRCA wild type) ovarian cancer cell line |
cytoprotective |
[41] |
| A2780 and SKOV3 ovarian cancer cell line |
cytoprotective |
[42] |
| LNCaP and C4-2B and PC-3 prostate cancer cell lines |
cytoprotective |
[44] |
| REH B-cell precursor acute lymphoblastic leukemia (ALL) cell line |
cytoprotective |
[47] |
| H460 non-small cell lung cancer and HCT116 colon cancer cell lines |
nonprotective |
[48] |
| Niraparib |
TU212 and TU686 laryngeal squamous cell carcinoma (LSCC) cell lines |
cytoprotective |
[49] |
| Huh7 and HepG2 hepatocellular carcinoma cell lines |
cytoprotective |
[25] |
| spiky ovarian cancer cells and BT474 mammary cancer cells |
cytotoxic |
[50] |
| SKOV3 and A2780 ovarian cancer cell lines |
cytotoxic |
[51] |
| H460 non-small cell lung cancer and HCT116 colon cancer cell lines |
non-protective |
[48] |
| Talazoparib |
pediatric chronic myeloid leukemia cells |
cytoprotective |
[52] |
| MCF-7, BRCA1-KO MCF-7, MDA-MB-231, T47-D, MDA-MB-453 and SKBR-3 breast cancer cell line |
Cytoprotective except for BRCA1-KO MCF-7, showed non protective |
[53] |
| MCF-7 and MDA-MB-231 breast cancer cell lines |
cytoprotective |
[54] |
| Rucaparib |
MiaPaCa-2 and Capan-1 |
cytotoxic |
[56] |
